Cancer Immunology Reserch

Cancer Immunol Res. 2025 May 8. doi: 10.1158/2326-6066.CIR-25-0019. Online ahead of print. ABSTRACT A key treatment for patients with multiple myeloma is high-dose melphalan followed by autologous stem cell transplant (ASCT). It can provide a deep response with long-term remission. However, some patients progress quickly, and it is not clear why that is. Here, we … Read more

Cancer Immunol Res. 2025 May 5. doi: 10.1158/2326-6066.CIR-24-0419. Online ahead of print. ABSTRACT Immune evasion is a hallmark of gliomas, yet the genetic mechanisms by which tumors escape immune surveillance remain incompletely understood. In this study, we systematically examined the presence of somatic mutations in human leukocyte antigen (HLA) genes and genes encoding proteins involved … Read more

Cancer Immunol Res. 2025 May 5. doi: 10.1158/2326-6066.CIR-24-1194. Online ahead of print. ABSTRACT Colorectal cancer (CRC) creates a suppressive tumor immune microenvironment (TIME) which leads to tumor progression and resistance to immune checkpoint inhibitor (ICI) therapy. Ubiquitin-specific peptidase 15 (USP15) broadly regulates immune responses and immune cell differentiation, but its involvement in shaping the TIME … Read more

Cancer Immunol Res. 2025 May 2;13(5):617. doi: 10.1158/2326-6066.CIR-13-5-WWR. NO ABSTRACT PMID:40313108 | DOI:10.1158/2326-6066.CIR-13-5-WWR

Cancer Immunol Res. 2025 Apr 29. doi: 10.1158/2326-6066.CIR-24-1179. Online ahead of print. ABSTRACT The efficacy of immunotherapy targeting PD-1/PD-L1 in gastric cancer (GC) depends on PD-L1 expression level and infiltration of immune cells within the tumor microenvironment (TME). While methyltransferase-like 3 (METTL3) plays a role in the development and progression of GC, its mechanism of … Read more

Cancer Immunol Res. 2025 Apr 29:OF1-OF14. doi: 10.1158/2326-6066.CIR-24-1347. Online ahead of print. ABSTRACT Patients can develop human anti-mouse immune responses against CD19-specific chimeric antigen receptor (CAR) T cells due to the use of a murine CD19-specific single-chain variable fragment to redirect T cells. We screened a yeast display library to identify an array of fully … Read more

Cancer Immunol Res. 2025 Apr 28. doi: 10.1158/2326-6066.CIR-24-0852. Online ahead of print. ABSTRACT Adaptive Natural Killer (aNK) cells have emerged as a subset of NK cells with memory-like properties and specific cytotoxicity, offering promising therapeutic potential in cancer immunotherapy. In this study, we explored the role of aNK cells in high-grade serous ovarian cancer (HGSOC), … Read more

Cancer Immunol Res. 2025 Apr 22. doi: 10.1158/2326-6066.CIR-24-0306. Online ahead of print. ABSTRACT Spontaneous remission in patients with various cancers has been reported. Some patients with adult T-cell leukemia-lymphoma (ATL), have experienced spontaneous remission, although mechanisms for this remain unknown. In this study, we analyzed ATL cells and human T-cell leukemia virus type 1 (HTLV-1) … Read more

Cancer Immunol Res. 2025 Apr 22. doi: 10.1158/2326-6066.CIR-24-0127. Online ahead of print. ABSTRACT NEDDylation is a post-translational modification whereby the ubiquitin-like molecule NEDD8 is attached to protein substrates in a process dependent on NEDD8 activating enzyme regulatory subunit (NAE1). NEDDylation is emerging as a regulator of cancer biology, but its precise role in antitumor immunity … Read more

Cancer Immunol Res. 2025 Apr 18. doi: 10.1158/2326-6066.CIR-24-0387. Online ahead of print. ABSTRACT Although initially assumed to be similar, immune checkpoint inhibitor (ICI)-induced autoimmunity can differ from spontaneous autoimmune disease regarding clinical presentation, pathogenesis and therapy. Despite limited pathogenetic understanding, ICI-induced colitis (irColitis), a common adverse event during ICI therapy, is treated analogously to its … Read more